Surrey LF, MacFarland SP, Chang F, Cao K, Rathi KS, Akgumus GT, et al. Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Med. 2019;11:32.
Google ScholarÂ
Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26:1742–53.
Google ScholarÂ
Inagaki C, Maeda D, Hatake K, Sato Y, Hashimoto K, Sakai D, et al. Clinical utility of next-generation sequencing-based panel testing under the universal health-care system in Japan: a retrospective analysis at a single university hospital. Cancers. 2021;13:1121.
Google ScholarÂ
Bertucci F, Goncalves A, Guille A, Adelaide J, Garnier S, Carbuccia N, et al. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Med. 2021;13:87.
Google ScholarÂ
Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J Clin Oncol. 2022;40:1231–58.
Google ScholarÂ
Lemmon CA, Zhou J, Hobbs B, Pennell NA. Modeling costs and life-years gained by population-wide next-generation sequencing or single-gene testing in nonsquamous non-small-cell lung cancer in the United States. JCO Precis Oncol. 2023;7:e2200294.
Google ScholarÂ
Bourke M, McInerney-Leo A, Steinberg J, Boughtwood T, Milch V, Ross AL, et al. The cost effectiveness of genomic medicine in cancer control: a systematic literature review. Appl Health Econ Health Policy. 2025;3:359–93.
Google ScholarÂ
Schilling C, Sjaaf F, Goranitis I, Dalziel K, Martyn M, Stark Z, et al. Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014-2023. Eur J Hum Genet. 2025;33:1044–50.
Google ScholarÂ
Omico. Cancer Screening Program – CaSP [Available from: https://www.omico.com.au/our-programs/cancer-screening-program-casp/.
Cooper WA, Amanuel B, Cooper C, Fox SB, Graftdyk JWA, Jessup P, et al. Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia. Pathology. 2025;57:425–36.
Google ScholarÂ
Australian Commission on Safety and Quality in Health Care. Requirements for medical testing for human genetic variation. 3rd ed. Sydney: ACSQHC; 2022. p. 31.
Furtado LV, Bifulco C, Dolderer D, Hsiao SJ, Kipp BR, Lindeman NI, et al. Recommendations for tumor mutational burden assay validation and reporting: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer. J Mol Diagn. 2024;26:653–68.
Google ScholarÂ
Hsiao SJ, Black D, Devereaux KA, Hagemann IS, Jennings LJ, Mandelker D, et al. Recommendations for clinical molecular laboratories for detection of homologous recombination deficiency in cancer: a joint consensus recommendation of the Association of Molecular Pathology, Association of Cancer Care Centers, and College of American Pathologists. J Mol Diagn. 2025;27:685–704.
National Pathology Accreditation Advisory Council. Requirements for human medical genome testing utilising massively parallel sequencing technologies. 1st ed. Canberra: Australian Government Department of Health; 2017. p. 25–6.
van de Haar J, Roepman P, Andre F, Balmana J, Castro E, Chakravarty D, et al. ESMO Recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol. 2024;35:954–67.
Google ScholarÂ
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
Google ScholarÂ
Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–8.
Google ScholarÂ
Johnson A, Zeng J, Bailey AM, Holla V, Litzenburger B, Lara-Guerra H, et al. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today. 2015;20:1433–8.
Google ScholarÂ
Sukhai MA, Craddock KJ, Thomas M, Hansen AR, Zhang T, Siu L, et al. A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genet Med. 2016;18:128–36.
Google ScholarÂ
Ritter DI, Roychowdhury S, Roy A, Rao S, Landrum MJ, Sonkin D, et al. Somatic cancer variant curation and harmonization through consensus minimum variant level data. Genome Med. 2016;8:117.
Google ScholarÂ
U.S. Food and Drug Administration. CDRH’S approach to tumor profiling next generation sequencing tests. Silver Spring, MD: U.S. Food & Drug Administration; 2017.
Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer. J Mol Diagn. 2017;19:4–23.
Google ScholarÂ
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29:1895–902.
Google ScholarÂ
Koeppel F, Muller E, Harle A, Guien C, Sujobert P, Trabelsi Grati O, et al. Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignancies. Eur J Cancer. 2021;159:1–15.
Google ScholarÂ
Mehta N, He R, Viswanatha DS. Internal standardization of the interpretation and reporting of sequence variants in hematologic neoplasms. Mol Diagn Ther. 2021;25:517–26.
Google ScholarÂ
Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022;24:986–98.
Google ScholarÂ
Lai A, Soucy A, El Achkar CM, Barkovich AJ, Cao Y, DiStefano M, et al. The ClinGen brain malformation variant curation expert panel: rules for somatic variants in AKT3, MTOR, PIK3CA, and PIK3R2. Genet Med. 2022;24:2240–8.
Google ScholarÂ
Tudini E, Andrews J, Lawrence DM, King-Smith SL, Baker N, Baxter L, et al. Shariant platform: enabling evidence sharing across Australian clinical genetic-testing laboratories to support variant interpretation. Am J Hum Genet. 2022;109:1960–73.
Google ScholarÂ
The Royal College of Pathologists of Australasia. Australian Health Genetics/Genomics Survey 2017. Report of Key Findings to: Department of Health. The Royal College of Pathologists of Australasia; 2019.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2025. Available from: https://www.nccn.org/guidelines/category_1.
Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062–D7.
Google ScholarÂ
Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet. 2017;49:170–4.
Google ScholarÂ
Medicines Australia. Medicines Matter 2022. ACT: Deakin; 2022.
Butow P, Davies G, Napier CE, Schlub T, Best MC, Bartley N, et al. Assessment of the value of tumor variation profiling perceived by patients with cancer. JAMA Netw Open. 2020;3:e204721.
Google ScholarÂ
Casolino R, Beer PA, Chakravarty D, Davis MB, Malapelle U, Mazzarella L, et al. Interpreting and integrating genomic tests results in clinical cancer care: overview and practical guidance. CA Cancer J Clin. 2024;74:264–85.
Google ScholarÂ
Therapeutic Goods Administration. Australian Public Assessment Report for Larotrectinib. Canberra: Australian Government; 2020.
Sirohi D, Schmidt RL, Aisner DL, Behdad A, Betz BL, Brown N, et al. Multi-institutional evaluation of interrater agreement of variant classification based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists standards and guidelines for the interpretation and reporting of sequence variants in cancer. J Mol Diagn. 2020;22:284–93.
Google ScholarÂ
Li MM, Cottrell CE, Pullambhatla M, Roy S, Temple-Smolkin RL, Turner SA, et al. Assessments of somatic variant classification using the Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists Guidelines. J Mol Diagn. 2023;25:69–86.
Google ScholarÂ
Perakis SO, Weber S, Zhou Q, Graf R, Hojas S, Riedl JM, et al. Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. ESMO Open. 2020;5:e000872.
Google ScholarÂ
Gould C, McBean M, Thompson E, Lickiss J, Tiong IS, Westerman D, et al. Observations from a national sample exchange program for molecular haematology testing. Pathology. 2024;56:540–7.
Google ScholarÂ
Yao J, Arcila ME, Ladanyi M, Hechtman JF. Pan-cancer biomarkers: changing the landscape of molecular testing. Arch Pathol Lab Med. 2021;145:692–8.
Google ScholarÂ
Thavaneswaran S, Ballinger M, Butow P, Meiser B, Goldstein D, Lin F, et al. The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey. Oncotarget. 2021;12:2169–76.
Google ScholarÂ
The National Oncology Alliance. Australian cancer genomics landscape assessment. Rare Cancers Australia; 2020. https://www.rarecancers.org.au/wp-content/uploads/2025/01/Genomic-Testing-Blueprint-Report.pdf.
West HJ, Lovly CM. Ferrying oncologists across the chasm of interpreting biomarker testing reports: systematic support needed to improve care and decrease disparities. JCO Oncol Pr. 2023;19:530–2.
Google ScholarÂ
Rare Cancers Australia, Australian Genomics. Advancing genomic-led cancer care in Australia. 2025. https://www.rarecancers.org.au/wp-content/uploads/2025/02/RCA5251-Advancing-Genomic-led-Cancer-Care-in-Australia_FA2.pdf.
